

INDICATIONS FOR CANCER GENETICS REFERRAL¹

January 2026

GENERAL GUIDANCE

Consider cancer genetics referral when there is/are:

- Three relatives on the same side of the family with similar or related cancers
- An individual or a close relative with two or more different cancers
- An individual or a close relative with cancer typically occurring in adulthood diagnosed at a younger age than expected (often less than age 50)
- Non-cancerous findings suggesting a recognized genetic condition (e.g., multiple colon polyps)
- A known cancer-related mutation in the family (e.g., *BRCA1*, *MLH1*, *MUTYH*, *TP53*, etc.)
- A rare cancer (e.g., medullary thyroid cancer, pheochromocytoma, etc.)
- A potential germline variant detected on tumor-based genomic testing
- An individual or a close relative with ovarian or pancreas cancer at any age
- An individual with a personal history of cancer suggestive of a hereditary cancer syndrome and an unknown or limited family history/structure, such as fewer than two first- or second-degree relatives having lived beyond age 45 in either lineage

Use the following checklists to aid in assessing whether a genetics referral is necessary for patients with the following:

- Breast cancer (page 2)
- Family history of breast cancer (page 3)
- Prostate cancer (page 4)
- Colorectal or Endometrial cancer (page 5)
- Melanoma (page 6)
- Renal cancer (page 7)
- Gastric cancer (page 8)
- Neuro-oncology (page 9)

¹These referral checklists are designed as simplified tools to assist in the clinic-based evaluation of patients and families. They do not reflect all high-risk criteria. These documents are expected to change over time. For questions regarding specific patients or families, or updated versions of these checklists, please contact the MaineHealth Cancer Risk and Prevention Program: Phone 207-396-7270; Fax 207-800-4237

Checklist for Breast Cancer Genetic Assessment
 For use in individuals with a personal history of breast cancer

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with hereditary cancer predisposition (e.g., <i>ATM</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>CHEK2</i> , <i>TP53</i> , <i>PALB2</i> , <i>PTEN</i> , etc.)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing (e.g., <i>BRCA1/2</i> only testing, testing 10+ yrs ago)
<input type="checkbox"/>	Potential germline variant detected on tumor-based genomic testing
<input type="checkbox"/>	Breast cancer at or before age 50
<input type="checkbox"/>	Triple negative breast cancer at any age
<input type="checkbox"/>	Male breast cancer at any age
<input type="checkbox"/>	To aid in treatment decisions (e.g., PARP inhibitors)
<input type="checkbox"/>	Multiple primary breast cancers at any age
<input type="checkbox"/>	Ashkenazi Jewish ancestry
<input type="checkbox"/>	In individuals with a personal history of breast cancer at any age and family history of cancer: <ul style="list-style-type: none"> <input type="checkbox"/> One or more relatives* with: <ul style="list-style-type: none"> ○ Breast cancer at or before age 50 ○ Metastatic prostate cancer ○ High- or very high-risk prostate cancer defined as stage T3a or greater, Gleason score of at least 8, or PSA >20 ng/mL ○ Male breast cancer, ovarian cancer or pancreatic cancer at any age <input type="checkbox"/> Two or more relatives* with: <ul style="list-style-type: none"> ○ Breast cancer and/or prostate cancer (any grade) at any age ○ Breast cancer, sarcoma, adrenocortical carcinoma, brain tumor, and/or leukemia (<i>suspicion for Li-Fraumeni syndrome</i>—see <i>NCCN for full criteria</i>) ○ Breast cancer, colon cancer, endometrial cancer, thyroid cancer, kidney cancer, macrocephaly, and/or GI hamartomatous polyps (<i>suspicion for Cowden syndrome</i>—see <i>NCCN for full criteria</i>) ○ Lobular breast cancer and/or diffuse gastric cancer (<i>suspicion for hereditary diffuse gastric cancer syndrome</i>—see <i>NCCN for full criteria</i>) ○ Breast cancer, GI cancer or polyps, ovarian sex cord tumors, pancreatic cancer, testicular Sertoli cell tumors, or childhood skin pigmentation (<i>suspicion for Peutz-Jeghers syndrome</i>—see <i>NCCN for full criteria</i>)

*1st: parents, siblings, children; 2nd: grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren;

3rd: cousins, great-grandparents, great-aunts/uncles, great-nieces/nephews, great-grandchildren.

Affected relatives should be on the same side of the family to meet the criteria.

Checklist for Breast Cancer Genetic Assessment
 For use in individuals with a **family history of breast cancer**

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with hereditary cancer predisposition (e.g., <i>ATM</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>CHEK2</i> , <i>TP53</i> , <i>PALB2</i> or <i>PTEN</i>)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing (e.g., <i>BRCA1/2</i> only testing, testing 10+ yrs ago)
<input type="checkbox"/>	Ashkenazi Jewish ancestry with a family history of breast cancer or prostate cancer, at any age
<input type="checkbox"/>	<p>In individuals with a family history of cancer in a first- or second-degree relative:</p> <ul style="list-style-type: none"> <input type="checkbox"/> One or more relatives with: <ul style="list-style-type: none"> ○ Breast cancer at 50 or younger ○ Triple negative breast cancer at any age ○ Multiple primary breast cancers ○ Metastatic prostate cancer ○ High- or very high-risk prostate cancer defined as stage T3a or greater, Gleason score of at least 8, or PSA >20 ng/mL ○ Male breast cancer, ovarian cancer or pancreatic cancer at any age ○ Diffuse gastric cancer at any age <input type="checkbox"/> Three or more relatives with: <ul style="list-style-type: none"> ○ Breast cancer and/or prostate cancer (any grade) at any age (<i>suspicion for hereditary breast and ovarian cancer syndrome</i>—see <i>NCCN for full criteria</i>) ○ Breast cancer, sarcoma, adrenocortical carcinoma, brain tumor, and/or leukemia (<i>suspicion for Li-Fraumeni syndrome</i>—see <i>NCCN for full criteria</i>) ○ Breast cancer, colon cancer, endometrial cancer, thyroid cancer, kidney cancer, macrocephaly, and/or GI hamartomatous polyps (<i>suspicion for Cowden syndrome</i>—see <i>NCCN for full criteria</i>) ○ Breast cancer, GI cancer or polyps, ovarian sex cord tumors, pancreatic cancer, testicular Sertoli cell tumors, or childhood skin pigmentation (<i>suspicion for Peutz-Jeghers syndrome</i>—see <i>NCCN for full criteria</i>)

* 1st: parents, siblings, children; 2nd: grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren.
 Affected relatives should be on the same side of the family to meet the criteria.

Checklist for Prostate Cancer Genetic Assessment
 For use in individuals with a personal history of prostate cancer

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with hereditary cancer predisposition (e.g., <i>ATM</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>CHEK2</i> , <i>TP53</i>)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing (e.g., <i>BRCA1/2</i> only testing, testing 10+ yrs ago)
<input type="checkbox"/>	Potential germline variant detected on tumor-based genomic testing
<input type="checkbox"/>	Metastatic prostate cancer
<input type="checkbox"/>	Prostate cancer in the high- or very high-risk group
<input type="checkbox"/>	Prostate cancer in the intermediate-risk group with intraductal/cribiform histology
<input type="checkbox"/>	Ashkenazi Jewish ancestry
<input type="checkbox"/>	In individuals with a personal history of prostate cancer at any age and family history of cancer: <ul style="list-style-type: none"> <input type="checkbox"/> One or more close blood relatives* with: <ul style="list-style-type: none"> <input type="radio"/> Metastatic prostate cancer <input type="radio"/> High- or very high-risk prostate cancer defined as stage T3a or greater, Gleason score of at least 8, or PSA >20 ng/mL <input type="radio"/> Breast cancer at 50 or younger <input type="radio"/> Triple-negative breast cancer at any age <input type="radio"/> Male breast cancer at any age <input type="radio"/> Ovarian cancer at any age <input type="radio"/> Pancreatic cancer at any age <input type="checkbox"/> Two or more relatives* with: <ul style="list-style-type: none"> <input type="radio"/> Either breast or prostate cancer (any grade) at any age <input type="checkbox"/> Three or more relatives* with: <ul style="list-style-type: none"> <input type="radio"/> Colorectal cancer, endometrial cancer, pancreatic cancer, gastric cancer, urothelial cancer, small intestine cancer (<i>suspicion for Lynch Syndrome- see NCCN for full criteria</i>)

* 1st: parents, siblings, children; 2nd: grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren;
 3rd: cousins, great-grandparents, great-aunts/uncles, great-nieces/nephews, great-grandchildren.
 Affected relatives should be on the same side of the family to meet the criteria.

Checklist for Colorectal and Endometrial Cancer Genetic Assessment

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with any hereditary cancer predisposition (e.g., <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i> , <i>EPCAM</i> , <i>MUTYH</i> , <i>APC</i>)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing (e.g., Lynch syndrome only testing, testing 10+ yrs ago)
<input type="checkbox"/>	Mismatch repair deficiency detected by tumor profiling (MSI-high or loss of expression on IHC), or potential germline variant detected on tumor-based genomic testing
<input type="checkbox"/>	Individuals with colorectal, endometrial or other Lynch syndrome (LS)-related cancer**: <input type="checkbox"/> Diagnosed before age 50 <input type="checkbox"/> Another LS-related cancer** (<i>including a second colorectal cancer</i>) <input type="checkbox"/> One or more first- or second-degree relatives* with a LS-related cancer** before age 50 <input type="checkbox"/> Two or more first- or second-degree relatives* with LS-related cancers** at any age
<input type="checkbox"/>	Individuals at risk for a hereditary polyposis syndrome: <input type="checkbox"/> 10 or more adenomas <input type="checkbox"/> Two or more hamartomas <input type="checkbox"/> Five or more serrated polyps, proximal to the rectum, with two or more being 1 cm or greater (<i>cumulative count over lifetime, includes hyperplastic polyps</i>) <input type="checkbox"/> 20 or more serrated polyps of any size (<i>cumulative count over lifetime, includes hyperplastic polyps</i>), <i>with 5 or more being proximal to the rectum</i> <input type="checkbox"/> Five or more juvenile polyps <input type="checkbox"/> Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE) <input type="checkbox"/> Desmoid tumor <input type="checkbox"/> Osteoma or supernumerary teeth <input type="checkbox"/> Hepatoblastoma <input type="checkbox"/> Papillary thyroid cancer, cribiform-morular variant
<input type="checkbox"/>	Individuals with family history of polyposis and affected family member unwilling/unable to have testing
<input type="checkbox"/>	Individuals with a family history of: <input type="checkbox"/> One or more first-degree relative(s)* with: <input type="radio"/> Colorectal or endometrial cancer before age 50, or <input type="radio"/> Colorectal or endometrial cancer at any age AND another LS-related cancer** <input type="checkbox"/> Two or more first- or second-degree relatives* with LS-related cancer** with one or more diagnosed before age 50 <input type="checkbox"/> Three or more first- or second-degree relatives* with LS-related cancer**, any age

* First-, second-, and third-degree relative(s) on the same side of the family. 1st= parents, siblings, children; 2nd= grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren; 3rd= first cousins, great-grandparents, great-aunts, great-uncles, great-nieces, great-nephews, great-grandchildren.

Affected relatives should be on the same side of the family to meet the criteria.

** LS-associated tumors= colorectal, endometrial, gastric, ovarian, pancreas, urothelial, brain (usually glioblastoma), biliary tract, small intestine, and sebaceous adenoma, carcinoma or keratoacanthoma

Checklist for Hereditary Melanoma Genetic Assessment

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with hereditary cancer predisposition (e.g., <i>BAP1</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>CDKN2A</i> , etc)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing (e.g., <i>BRCA1/2</i> only testing, testing 10+ yrs ago)
<input type="checkbox"/>	Potential germline variant detected on tumor-based genomic testing
<input type="checkbox"/>	Two or more invasive cutaneous melanomas (in an individual or family member)
<input type="checkbox"/>	Individual with invasive cutaneous melanoma that has a first-degree relative diagnosed with pancreatic cancer**
<input type="checkbox"/>	A mix of three of the following in an individual or family: <ul style="list-style-type: none"> <input type="checkbox"/> Invasive melanoma <input type="checkbox"/> Pancreatic cancer <input type="checkbox"/> Astrocytoma
<input type="checkbox"/>	Although formal guidelines do not exist, <i>BAP1</i> tumor predisposition syndrome (<i>BAP1</i> -TPDS) should be suspected if the individual has two or more <i>BAP1</i> -TPDS associated tumors ¹ , with the exception of two basal cell cancers and/or cutaneous melanomas ² <p>¹ In descending order of likelihood, <i>BAP1</i>-TPDS associated tumors include: <i>BAP1</i>-inactivated melanocytic tumor (i.e., atypical Spitz tumor), uveal melanoma, malignant mesothelioma, cutaneous melanoma, renal cell cancer, basal cell cancer, hepatocellular carcinoma, cholangiocarcinoma and meningioma.</p> <p>² GeneReviews website, accessed 1/16/2026</p>

*1st: parents, siblings, children; 2nd: grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren; 3rd: cousins, great-grandparents, great-aunts/uncles, great-nieces/nephews, great-grandchildren.

Affected relatives should be on the same side of the family to meet the criteria.

** Per NCCN guidelines, hereditary cancer genetic testing is recommended for anyone with a personal history of pancreatic cancer or a family history of pancreatic cancer in a first-degree relative.

Checklist for Renal Cancer Genetic Assessment

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with hereditary cancer predisposition (e.g., <i>BAP1</i> , <i>FH</i> , <i>FLCN</i> , <i>VHL</i> , etc.)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing
<input type="checkbox"/>	Potential germline variant detected on tumor-based genomic testing
<input type="checkbox"/>	Individual with kidney cancer with any of the following: <ul style="list-style-type: none"> <input type="checkbox"/> Diagnosed at 46 or younger <input type="checkbox"/> Bilateral or multifocal tumors at any age <input type="checkbox"/> Has one or more first or second degree* relative with kidney cancer
<input type="checkbox"/>	Individual whose tumors have the following features: <ul style="list-style-type: none"> <input type="checkbox"/> Multifocal papillary histology <input type="checkbox"/> Type 2 papillary kidney cancer with fumarate hydratase (FH) deficiency (<i>suspicion for Hereditary Leiomyomatosis and Renal Cell Carcinoma</i>- see NCCN for full criteria) <input type="checkbox"/> Chromophobe, oncocytoma, or oncocytic hybrid (<i>suspicion for Birt-Hogg-Dube</i>- see NCCN for full criteria) <input type="checkbox"/> Angiolipomas of the kidney** (<i>suspicion for tuberous sclerosis complex (TSC)</i>- see NCCN for full criteria) <input type="checkbox"/> Succinate dehydrogenase (SDH) deficiency (<i>suspicion for Hereditary Pheochromocytoma and Paraganglioma Syndrome</i>- see NCCN for full criteria)
<input type="checkbox"/>	Family history of two or more first or second degree* relatives with kidney cancer
<input type="checkbox"/>	Family history of one first degree relative with kidney cancer meeting criteria above and family member is unwilling/unable to have testing

* 1st: parents, siblings, children; 2nd: grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren; 3rd: cousins, great-grandparents, great-aunts/uncles, great-nieces/nephews, great-grandchildren.

Affected relatives should be on the same side of the family to meet the criteria.

** Referral to MaineHealth Pediatric Specialty Care – Genetics (Pediatric and Adult Genetics)

Checklist for Gastric Cancer Genetic Assessment

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with hereditary cancer predisposition (e.g., <i>APC</i> , <i>CDH1</i> , <i>MLH1</i> , <i>MSH2</i> , etc.)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing
<input type="checkbox"/>	Potential germline variant detected on tumor-based genomic testing
<input type="checkbox"/>	Gastric cancer before age 50
<input type="checkbox"/>	Diffuse gastric cancer (DGC) at any age
<input type="checkbox"/>	Gastric cancer at any age AND: <ul style="list-style-type: none"> <input type="checkbox"/> Two or more first- or second-degree relatives* with gastric cancer <input type="checkbox"/> One or more first- or second-degree relatives with gastric cancer diagnosis before age 50 <input type="checkbox"/> One or more relatives with diffuse gastric cancer <input type="checkbox"/> Family history of juvenile polyps or gastrointestinal polyposis <input type="checkbox"/> Personal history of second primary cancer(s) associated with Lynch syndrome (LS)** <input type="checkbox"/> Family history in a first- or second-degree relative of LS-related cancer diagnosed before age 50, or 2 or more first- or second-degree relatives at any age
<input type="checkbox"/>	Family history of gastric cancer and/or cancers associated with LS** <ul style="list-style-type: none"> <input type="checkbox"/> In two first- or second-degree relatives with one diagnosis before age 50 <input type="checkbox"/> In two first- or second-degree relatives with at least one confirmed to be DGC at any age <input type="checkbox"/> In three first- or second-degree relatives regardless of age <input type="checkbox"/> And a relative with juvenile polyps or gastrointestinal polyposis

* 1st: parents, siblings, children; 2nd: grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren; 3rd: cousins, great-grandparents, great-aunts/uncles, great-nieces/nephews, great-grandchildren.

Affected relatives should be on the same side of the family to meet the criteria.

** LS-associated tumors= colorectal, endometrial, gastric, ovarian, pancreas, urothelial, brain (usually glioblastoma), biliary tract, small intestine, and sebaceous adenoma, carcinoma or keratoacanthoma

Checklist for Neuro-oncology Cancer Genetic Assessment

Consider genetic assessment (to include consideration of genetic testing) for any patient who meets one or more of the following criteria:

✓ if present	Criteria
<input type="checkbox"/>	A family member* with any germline pathogenic/likely pathogenic variant in a gene associated with hereditary cancer predisposition (e.g., <i>NF2</i> , <i>PTCH1</i> , <i>PTEN</i> , <i>TP53</i> , etc.)
<input type="checkbox"/>	Individual who previously tested negative with limited analysis testing
<input type="checkbox"/>	Potential germline variant detected on tumor-based genomic testing
<input type="checkbox"/>	Individuals with the following tumor types related to risk: <ul style="list-style-type: none"> <input type="checkbox"/> Adrenocortical carcinoma <input type="checkbox"/> Choroid plexus carcinoma <input type="checkbox"/> Rhabdomyosarcoma of embryonal anaplastic subtype ** <input type="checkbox"/> Adult Lhermitte-Duclos disease (dysplastic gangliocytoma of the cerebellum) <input type="checkbox"/> CNS or retinal hemangioblastoma <input type="checkbox"/> Multiple cortical tubers and/or radial migration lines ** <input type="checkbox"/> Subependymal giant cell astrocytoma (SEGA) and/or two or more subependymal nodules ** <input type="checkbox"/> Optic pathway glioma ** <input type="checkbox"/> Bilateral vestibular schwannoma/acoustic neuroma or unilateral vestibular schwannoma/acoustic neuroma with other NF2 features
<input type="checkbox"/>	Individuals with a medulloblastoma or glioblastoma AND colorectal cancer or multiple colorectal adenomas (<i>suspicion for Familial Adenomatous Polyposis or Lynch syndrome</i> —see NCCN for full criteria)
<input type="checkbox"/>	Individuals with a medulloblastoma and: <ul style="list-style-type: none"> <input type="checkbox"/> Multiple nevoid basal cell carcinomas (more than 5 lifetime or a BCC before age 30 y), jaw keratocysts, congenital skeletal abnormalities (<i>suspicion for Gorlin syndrome</i>)
<input type="checkbox"/>	Individuals with a brain tumor diagnosed under age 50, or brain tumor diagnosed at any age AND a personal or family history of any two of the following cancers: <ul style="list-style-type: none"> <input type="checkbox"/> Colon, endometrial, ovarian, pancreatic, urothelial, biliary tract, and small intestine (<i>suspicion for Lynch syndrome</i>—see NCCN for full criteria)
<input type="checkbox"/>	Individual with personal and/or family history of a mix of the following tumor types: <ul style="list-style-type: none"> <input type="checkbox"/> Astrocytoma, melanoma or pancreas cancer (<i>suspicion for Familial Atypical Multiple Mole Melanoma Syndrome</i> - see NCCN for criteria)
<input type="checkbox"/>	Two or more relatives with: <ul style="list-style-type: none"> <input type="checkbox"/> Brain tumor, breast cancer, sarcoma, adrenocortical carcinoma, and/or leukemia (<i>suspicion for Li-Fraumeni syndrome</i>—see NCCN for full criteria)

*1st: parents, siblings, children; 2nd: grandparents, aunts, uncles, nieces, nephews, half-siblings, grandchildren; 3rd: cousins, great-grandparents, great-aunts/uncles, great-nieces/nephews, great-grandchildren.

Affected relatives should be on the same side of the family to meet the criteria.

** Referral to MaineHealth Pediatric Specialty Care – Genetics (Pediatric and Adult Genetics)